{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=98", "query": { "intervention": "Part 3", "page": 98 }, "page_size": 10 }, "pagination": { "page": 98, "page_size": 10, "total_count": 4023, "total_pages": 403, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=99&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+3&page=97&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T00:25:23.836Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04206332", "title": "Trial to Evaluate CIS43LS in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria" ], "interventions": [ { "name": "VRC-MALMAB0100-00-AB", "type": "DRUG" }, { "name": "Plasmodium falciparum (P. falciparum) sporozoite challenge", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 71, "start_date": "2020-01-07", "completion_date": "2022-02-28", "has_results": true, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Bethesda, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04206332" }, { "nct_id": "NCT07129993", "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-09-26", "completion_date": "2030-01-22", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 38, "location_summary": "Fullerton, California • Glendale, California • La Jolla, California + 34 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07129993" }, { "nct_id": "NCT01502800", "title": "Clinical Trial of ARQ 761 in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ARQ 761", "type": "DRUG" }, { "name": "ARQ 761 Weekly Administration", "type": "DRUG" }, { "name": "Bi-Weekly Administration of ARQ 761", "type": "DRUG" }, { "name": "Two Consecutive Weeks Administration of ARQ 761 with one week of rest", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2011-12-29", "completion_date": "2019-03", "has_results": false, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01502800" }, { "nct_id": "NCT04234113", "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Thyroid Cancer", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Melanoma", "Merkel Cell Carcinoma", "Skin Squamous Cell Carcinoma", "Microsatellite Instability High", "Triple Negative Breast Cancer", "Mesothelioma", "Thymic Cancer", "Cervical Cancer", "Biliary Tract Cancer", "Hepatocellular Carcinoma", "Ovarian Cancer", "Gastric Cancer", "Head and Neck Squamous Cell Carcinoma", "Anal Cancer" ], "interventions": [ { "name": "Nanrilkefusp alfa", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SOTIO Biotech AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2019-06-13", "completion_date": "2024-11-27", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Pittsburgh, Pennsylvania • Houston, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04234113" }, { "nct_id": "NCT03265080", "title": "A Study of ADXS-NEO Expressing Personalized Tumor Antigens", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colon Cancer Metastatic", "Head and Neck Cancer Metastatic", "Metastatic Non-Small Cell Lung Cancer", "Urothelial Carcinoma", "Metastatic Melanoma" ], "interventions": [ { "name": "ADXS-NEO", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Advaxis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2018-03-28", "completion_date": "2020-11-12", "has_results": false, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • New Orleans, Louisiana + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Morristown", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03265080" }, { "nct_id": "NCT06617546", "title": "SAD and MAD Study of FTX-101 in Healthy Male Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "FTX-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Find Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "MALE", "summary": "18 Years to 59 Years · Male only" }, "enrollment_count": 49, "start_date": "2024-10-14", "completion_date": "2025-04-17", "has_results": false, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06617546" }, { "nct_id": "NCT07258719", "title": "Aromatherapy's Impact on Test Anxiety in College Students: A Mixed Methods Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety" ], "interventions": [ { "name": "Essential Oil 1", "type": "OTHER" }, { "name": "Essential Oil 2", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Jenalee Hinds", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 20, "start_date": "2025-09-18", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07258719" }, { "nct_id": "NCT05945628", "title": "Basic Experimental Study of Hippocampal Memory Functions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Memory" ], "interventions": [ { "name": "Different cognitive and memory demands during the memory experiment", "type": "BEHAVIORAL" }, { "name": "Different electrical stimulation parameters during cognitive and memory demands", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 66, "start_date": "2023-01-16", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945628" }, { "nct_id": "NCT07231471", "title": "Platelet Rich Plasma for Musculoskeletal Conditions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Osteoarthritis (OA)", "Osteoarthritis (OA) of the Knee", "Osteoarthritis (OA) of the Hip", "Osteoarthritis (OA) of the Shoulder", "Osteoarthritis Ankle", "Elbow Osteoarthritis", "Epicondylitis of the Elbow", "Plantar Fasciitis of Both Feet", "Tendinopathy" ], "interventions": [ { "name": "Platelet Rich Plasma Injection", "type": "BIOLOGICAL" }, { "name": "Platelet Rich Plasma Preparation", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10000, "start_date": "2025-12-29", "completion_date": "2035-01-01", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07231471" }, { "nct_id": "NCT00980330", "title": "A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peg-IFN-alfa-2a (P)", "type": "DRUG" }, { "name": "Ribavirin (R)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tibotec Pharmaceuticals, Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 463, "start_date": "2009-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-11-14T00:25:23.836Z", "location_count": 17, "location_summary": "La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00980330" } ] }